CD274 and neoplasm: PD-L1 expression assessed by immunohistochemistry in tumor tissue has been approved by the FDA as a standard biomarker for ICIs in NSCLC patients as a companion or complementary diagnostic test for different PD-1/PD-L1 inhibitor drugs [56].